499
Participants
Start Date
March 20, 2019
Primary Completion Date
January 13, 2025
Study Completion Date
December 31, 2027
Botensilimab
An Fc-engineered anti-CTLA-4 monoclonal antibody
Balstilimab
A fully human monoclonal anti-PD-1 antibody
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
University of Miami Sylvester Comprehensive Cancer Center, Miami
MD Anderson Cancer Center, Houston
The University of Texas Health Science Center at San Antonio, San Antonio
University of Colorado, Aurora
HonorHealth Research Institute, Scottsdale
The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, Los Angeles
University of Southern California Norris Comprehensive Cancer Center, Los Angeles
UCLA Santa Monica Hematology Oncology, Los Angeles
Saint John's Cancer Institute, Santa Monica
City of Hope Comprehensive Cancer Center, Duarte
Providence Portland Cancer Center, Portland
Yale Cancer Center, New Haven
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Royal Marsden Hospital NHS Foundation Trust, London
Lead Sponsor
Agenus Inc.
INDUSTRY